Information for Healthcare Professionals
FORCE supports healthcare professionals
If you're a healthcare professional caring for individuals and families affected by hereditary cancer, FORCE has evidence-informed tools, education and support resources to facilitate shared decision-making, and compassionate, informed care to help.
Help Your Patients Find Support
FORCE support programs include virtual community meetings, trained guidance from peer navigators and community message boards. We offer your patients multiple ways to connect with others in a safe, supportive environment. Download our flyer with all our support programs.
Support Meetings & Events
FORCE's Support Meetings and Events Calendar provides details on upcoming support meetings, webinars and partner events.
1 to 1 Support & Navigation
FORCE's Peer Navigation Program connects those seeking support with a trained peer navigator who shares a similar experience.
Spotlight
Looking for the latest guidelines?
FORCE provides gene-specific summaries on cancer risk, screening, prevention and treatment guidelines, and resources for individuals with inherited cancer risk.
Customizable Resources
Add your logo and contact info to FORCE materials
FORCE’s resource center allows you to personalize FORCE publications and genetic test result disclosure letters with your contact information and logo for printing or sharing on demand. We also provide links and QR codes to curated content for specific genes, which you can use within your own materials.
Insurance Coverage & Appeals
Find information on insurance coverage and reimbursement for health insurance appeals. Our customizable insurance appeal letters are designed to help you and your patients quickly appeal insurance denials.
Find Research Studies Enrolling People with Inherited Mutations
Use our search and enroll tool to connect your patients to the latest cancer prevention, treatment and quality-of-life studies enrolling people with or at high risk for hereditary cancers.
This study is testing a new targeted drug called daraxonrasib to see if it helps people with metastatic pancreatic cancer live longer or keep their cancer from growing longer than standard chemotherapy alone. Researchers are...
This study is for adults with advanced/metastatic HR-positive, HER2-negative advanced or metastatic breast cancer who have previously been treated with a CDK4/6 inhibitor and have received two or less treatments for their advanced metastatic breast...
This study tests whether COM701 (an anti‑PVRIG immunotherapy) given every 3 weeks as maintenance can delay cancer growth after a good response to platinum chemotherapy. Adults with relapsed platinum‑sensitive ovarian, fallopian tube, or primary peritoneal...
Go Behind the Headlines
Force's XRAY program shares easy-to-understand information on the latest cancer research.
Study : Mutations in familial melanoma genes and cancer risk
Researchers studied nearly 700,000 people from the United States and the United Kingdom to learn how common mutations in familial melanoma genes are in the general population. They found that these mutations may be more...
Study : GLP-1 drugs and breast cancer: results from ASCO 2026
Studies presented at the 2026 ASCO Annual Meeting looked at GLP-1 drugs in relation to breast cancer prevention and survival. Across these early studies, people taking GLP-1s drugs often had better breast cancer outcomes than...
Study : Understanding inherited breast cancer risk in young Black women
This study looked at genetic testing for Black women diagnosed with breast cancer at age 50 or younger. The study found that about 15% of young Black women had an inherited mutation in a known...
Quickly share FORCE resources with just a few clicks!
FORCE’s Healthcare Provider Toolkit makes it easy to distribute resources across your favorite social media platforms.